Harvard Bioscience, a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately.
Eisai Inc. has announced the appointments of Yuji Matsue as chairman and chief executive officer...
Avantor Performance Materials, a global manufacturer and supplier of high-performance...
Endo International has appointed Susan Hall, Ph.D. as executive vice president, chief scientific...
Roche announced today that William Pao, M.D., Ph.D., Professor of Medicine and Head of the Hematology-Oncology Division at Vanderbilt University Medical Center in the US, will join Roche Pharma Research and Early Development (pRED) as Global Head of the Oncology Disease and Translational Area.
Horizon Pharma today announced the appointment of Robert F. Carey as executive vice president and chief business officer, bringing a broad base of healthcare investment banking experience.
Hospira today announced that David J. Endicott has been named President, Hospira Medical Devices, effective March 10, 2014. In this newly created role, Mr. Endicott will have responsibility for establishing a fully integrated device organization.
First the teenager survived a rare cancer. Then she wanted to study it, spurring a study that helped scientists find a weird gene flaw that might play a role in how the tumor strikes.
Andrew Sandford joins Catalent as Vice President Business Development, Biologics, and will focus on growth of the company’s existing biologics offerings and, Dr. Jennifer Mitcham jas been appointed Director, Business Development for Antibody-Drug Conjugates (ADC), Biologics.
Jazz Pharmaceuticals has announced that Kathryn Falberg, executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests. Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period.
Pharmaceutical Product Development, LLC (PPD) has appointed Patrick Bennett as executive director of laboratory operations for a new biomarker services division of its bioanalytical laboratory.
OsoBio has appointed Paul W. Stoker, Ph.D., director of its chemistry and microbiology laboratories. Stoker fills a position vacated when Kathleen Larese, OsoBio’s previous director of laboratories, became the company’s director of technical operations.
Jean-Christophe Tellier, currently UCB’s Executive Vice President, Biopharma Brands and Solutions, will be appointed Chief Executive Officer-Elect and Chairman of the Executive Committee as of March 1, 2014. Jean-Christophe Tellier will also be proposed to be appointed as a member of the Board of Directors at the next Annual General Meeting of Shareholders on April 24, 2014.
EMD Serono, Inc. announced today the recent appointments of Gary Zieziula as the company’s Chief Commercial Officer, Allene Diaz as Senior Vice President of Managed Markets, Lisa Buffington as Vice President of US Communications, Alexander Kuta as Vice President and Head of US Regulatory Affairs, and Michael Ruggiero as Vice President of US Government Affairs and Policy.
Actavis plc has announced a realignment of its global strategic business structure to maximize the company's position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.
Integrated Project Services, Inc. (IPS), a full-service engineering, construction, commissioning and qualification firm, today announced the appointment of Scott Corbin as Regional Manager, Compliance for the New England region.
ISPE announced today that CEO Nancy Berg will leave the Society when her three year contract is completed at the end of 2014.
Mayne Pharma Group Limited has named Stefan Cross as president of Mayne Pharma USA. Cross is responsible for leading all of Mayne Pharma’s existing business operations in the United States, and for spearheading new business development initiatives.
Gilead Sciences, Inc. today announced several promotions within the company’s senior management team.
Purdue Pharma L.P. today announced that the company's Board of Directors has appointed Mark Timney as President and Chief Executive Officer.
Shire plc today announces that Matthew Emmens will retire as Non-Executive Chairman and Susan Kilsby, Chairman of Shire's Audit, Compliance & Risk Committee will succeed him after the conclusion of Shire's AGM on 29 April 2014.
Bayer HealthCare to Invest in Manufacturing Operations as Next Step in Recent Animal Health Business AcquisitionJanuary 20, 2014 2:57 pm | News | Comments
Bayer HealthCare LLC has announced that the company will be improving efficiency and investing in its manufacturing operations in Missouri. The company will combine and transfer operations from three locations in the St. Joseph area to one beginning this year.
A Mississippi drug maker has laid off about 75 employees, leaving questions about its future and whether it has to repay economic development money. Pharma Pac LLC made the layoffs Dec. 19, according to a notice filed with the Mississippi Department of Employment Security.
Actavis has announced an updated business structure for its U.S. Specialty Brands business designed to maximize the company's position in key therapeutic areas and position it for continued long-term growth.
Amgen said Thursday that Chief Financial Officer Jonathan Peacock is leaving the company to pursue other opportunities.
Teva Pharmaceutical Industries Ltd today announced that Erez Vigodman, 54, has been appointed President and Chief Executive Officer, effective February 11, 2014. Mr. Vigodman will succeed acting President and CEO Eyal Desheh, who will return to his previous position as Group EVP and Chief Financial Officer of the company.
KaloBios Pharmaceuticals, Inc. has announced the appointment of Harry Lam, Ph.D. as Head of Manufacturing. Dr. Lam brings to KaloBios more than 28 years of experience in biopharmaceutical manufacturing, including 17 years at Genentech.
Tekmira Pharmaceuticals Corporation has announced a reorganization of its leadership team. As part of these changes, effective January 6, 2014, Dr. Michael Abrams will join the company as Executive Vice President and Chief Discovery Officer, and Dr. Ian MacLachlan will head a newly formed group focused on medical countermeasures as Executive Vice President and Chief Technical Officer.
Ajinomoto Althea Inc., a CMO providing development and manufacturing services for biotechnology and pharmaceutical companies, announced today the appointment of J. David Enloe Jr. as President and CEO. Mr. Enloe will be responsible for developing strategies to support the company's continued growth.
- Page 1